Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 276918, 7 pages
http://dx.doi.org/10.1155/2014/276918
Review Article

Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?

1Department of Paediatrics, Hospital Luigi Sacco, Via GB Grassi 74, 20157 Milan, Italy
2Unit of Clinical Pharmacology, Hospital Luigi Sacco, Via GB Grassi 74, 20157 Milan, Italy

Received 17 October 2013; Revised 22 December 2013; Accepted 23 December 2013; Published 12 January 2014

Academic Editor: Allegaert Karel

Copyright © 2014 Valentina Giudici et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Marcus, H. A. Flynn, F. C. Blow, and K. L. Barry, “Depressive symptoms among pregnant women screened in obstetrics settings,” Journal of Women's Health, vol. 12, no. 4, pp. 373–380, 2003. View at Google Scholar · View at Scopus
  2. L. Andersson, I. Sundström-Poromaa, M. Bixo, M. Wulff, K. Bondestam, and M. Åström, “Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study,” The American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 148–154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. K. A. Yonkers, K. L. Wisner, D. E. Stewart et al., “The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists,” General Hospital Psychiatry, vol. 31, no. 5, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. National Institute for Clinical Excellence, “NICE antenatal and postnatal mental health,” 2007.
  5. C. Bellantuono, G. Migliarese, and S. Gentile, “Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review,” Human Psychopharmacology, vol. 22, no. 3, pp. 121–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Kievet, K. Dolman, and A. Honig, “The use of psychotropic medication during pregnancy: how about the newborn?” Neuropsychiatric Disease and Treatment, vol. 9, pp. 1257–1266, 2013. View at Google Scholar
  7. N. Boucher, A. Bairam, and L. Beaulac-Baillargeon, “A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 334–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman, “Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data,” Archives of General Psychiatry, vol. 63, no. 8, pp. 898–906, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Klinger and P. Merlob, “Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome,” Israel Journal of Psychiatry and Related Sciences, vol. 45, no. 2, pp. 107–113, 2008. View at Google Scholar · View at Scopus
  10. M. L. Hudak, “Tan RC neonatal drug withdrawal,” Pediatrics, vol. 129, no. 2, pp. e540–e560, 2012. View at Google Scholar
  11. S. D. Sie, J. M. B. Wennink, J. J. van Driel et al., “Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation,” Archives of Disease in Childhood, vol. 97, no. 6, pp. F472–F476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. T. F. Oberlander, S. Misri, C. E. Fitzgerald, X. Kostaras, D. Rurak, and W. Riggs, “Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure,” Journal of Clinical Psychiatry, vol. 65, no. 2, pp. 230–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. E. J. Sanz, C. De-las-Cuevas, A. Kiuru, A. Bate, and R. Edwards, “Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis,” The Lancet, vol. 365, no. 9458, pp. 482–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. L. Moses-Kolko, D. Bogen, J. Perel et al., “Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications,” Journal of the American Medical Association, vol. 293, no. 19, pp. 2372–2383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Laine, T. Heikkinen, U. Ekblad, and P. Kero, “Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations,” Archives of General Psychiatry, vol. 60, no. 7, pp. 720–726, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Heikkinen, U. Ekblad, P. Palo, and K. Laine, “Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation,” Clinical Pharmacology and Therapeutics, vol. 73, no. 4, pp. 330–337, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Costei, E. Kozer, T. Ho, S. Ito, and G. Koren, “Perinatal outcome following third trimester exposure to paroxetine,” Archives of Pediatrics and Adolescent Medicine, vol. 156, no. 11, pp. 1129–1132, 2002. View at Google Scholar · View at Scopus
  18. B. G. Pollock, R. E. Ferrell, B. H. Mulsant et al., “Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression,” Neuropsychopharmacology, vol. 23, no. 5, pp. 587–590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. T. F. Oberlander, R. J. Bonaguro, S. Misri, M. Papsdorf, C. J. D. Ross, and E. M. Simpson, “Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications,” Molecular Psychiatry, vol. 13, no. 1, pp. 65–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Laine, J. Kytölä, and L. Bertilsson, “Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy,” Therapeutic Drug Monitoring, vol. 26, no. 6, pp. 685–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Stiskal, “Defective alleles may not have contributed to adverse effects,” Therapeutic Drug Monitoring, vol. 28, no. 1, p. 142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Hilli, T. Heikkinen, R. Rontu et al., “MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs,” European Neuropsychopharmacology, vol. 19, no. 5, pp. 363–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. R. Hutson, G. Koren, and S. G. Matthews, “Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology,” Placenta, vol. 31, no. 5, pp. 351–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kato, T. Fukuda, A. Serretti et al., “ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 2, pp. 398–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. O. L. de Klerk, I. M. Nolte, P. M. Bet et al., “ABCB1 gene variants influence tolerance to selectiveserotonin reuptake inhibitors in a large sample of Dutch cases with majordepressive disorder,” The Pharmacogenomics Journal, vol. 13, no. 4, pp. 349–353, 2013. View at Google Scholar
  26. J. Ø. Berle and O. Spigset, “Antidepressant use during breastfeeding,” Current Women's Health Reviews, vol. 7, no. 1, pp. 28–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Ø. Berle, V. M. Steen, T. O. Aamo, H. Breilid, K. Zahlsen, and O. Spigset, “Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes,” Journal of Clinical Psychiatry, vol. 65, no. 9, pp. 1228–1234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. F. F. T. Ververs, H. A. M. Voorbij, P. Zwarts et al., “Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy,” Clinical Pharmacokinetics, vol. 48, no. 10, pp. 677–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. D. M. Matsui, “Therapeutic drug monitoring in pregnancy,” Therapeutic Drug Monitoring, vol. 34, pp. 507–511, 2012. View at Google Scholar